Eventide Asset Management Portfolio
13F Holdings & Position Changes — Last filed Aug 14, 2026
13F Holdings & Position Changes — Last filed Aug 14, 2026
Values-based investment firm with significant biotech allocation. Kuruvilla—a physician, engineer, and PhD—leads a team that evaluates companies on both financial merit and alignment with ethical principles. Known for holding high-conviction biotech positions alongside broader healthcare and technology investments.
Eventide Asset Management is a $6B biotech-focused hedge fund managed by Finny Kuruvilla, MD, PhD. As of their latest 13F filing (Q2 2026), the fund holds 234 positions worth $6.3B. This quarter they initiated 30 new positions and exited 156. Their largest holding is GH ($293.8M).
Eventide initiated 30 new positions and increased 130 this quarter. Portfolio grew +22.4% to $6.3B. 732 upcoming catalysts across holdings.
Portfolio Value (13F)
$6.3B
Holdings
234
Top 10 Concentration
27.6%
QoQ Change
+22.4%
Turnover
3.1%
Portfolio Value Trend
Be first to know when Eventide Asset Management files next quarter
Get an email the moment new buys, exits, and conviction changes hit. Free 14-day trial.
| # | Ticker | Company | Change | Value | % of Portfolio | SI % Float ? | Trend |
|---|---|---|---|---|---|---|---|
| 1 | GH | Guardant Health Inc. | Decreased↓3Q | $293.8M | 4.66% | — | |
| 2 | LRCX | Lam Research Corp. | Decreased | $291.7M | 4.63% | — | |
| 3 | XMTR | Xometry, Inc. | Decreased | $208.4M | 3.30% | — | |
| 4 | TT | Trane Technologies plc | Increased↑3Q | $203.5M | 3.23% | 1.3% | |
| 5 | MIRM | Mirum Pharmaceuticals Inc. | Decreased↓3Q | $146.2M | 2.32% | — | |
| 6 | UTHR | United Therapeutics Corporation | Increased | $131.8M | 2.09% | — | |
| 7 | GEV | GE Vernova Inc. | Decreased↓3Q | $124.7M | 1.98% | 3.0% | |
| 8 | ARGX | argenx SE | Held↑2Q | $116.6M | 1.85% | — | |
| 9 | SRRK | Scholar Rock Holding Corp. | Decreased↓2Q | $116.1M | 1.84% | 18.7% | |
| 10 | RYTM | Rhythm Pharmaceuticals Inc. | Increased↑2Q | $104.7M | 1.66% | 14.9% |
Share changes reflect active decisions. Value changes include price moves.
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
See all 234 holdings (you're viewing the top 10), plus 3 quarters of position history.
No charge for 14 days · Cancel anytime
Eventide Asset Management held 234 biotech stocks in their 13F portfolio this quarter. Their top positions include GH, LRCX, XMTR, TT, MIRM. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
Eventide Asset Management's tracked biotech portfolio is worth $6.3B across 234 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
Eventide Asset Management initiated 30 new positions this quarter, including AVLN, SNX, ORKA, SYRE, BRCB and 25 more. They also increased 130 existing positions.
Eventide Asset Management fully exited 156 positions this quarter, including APLS, LIFX, PRTA, NBIS, ACAD and 151 more. They also trimmed 63 existing positions.
Values-based investment firm with significant biotech allocation. Kuruvilla—a physician, engineer, and PhD—leads a team that evaluates companies on both financial merit and alignment with ethical principles. Known for holding high-conviction biotech positions alongside broader healthcare and technology investments.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free Trial